10-Q: Stepan Q3 Earnings Plunge Amid Surfactant Weakness

Stepan Company reports a significant drop in Q3 net income and diluted EPS, primarily driven by lower surfactant profitability and higher interest expenses, despite overall sales growth.

Summary

• Net sales for the three months ended September 30, 2025, increased by 8% to $590.3 million, up from $546.8 million in the prior year quarter.
• Net sales for the nine months ended September 30, 2025, rose by 7% to $1,778.2 million, compared to $1,654.7 million in the same period of 2024.
• Net income for Q3 2025 was $10.8 million ($0.47 per diluted share), a 54.1% decrease from $23.6 million ($1.03 per diluted share) in Q3 2024.
• Net income for the first nine months of 2025 was $41.9 million ($1.83 per diluted share), down 10.9% from $47.0 million ($2.05 per diluted share) in the prior year period.
• Operating income for Q3 2025 decreased by 9% to $21.8 million, while for the nine months, it increased by 8% to $68.0 million.
• EBITDA for Q3 2025 increased by 6% to $56.1 million, and for the nine months, it rose by 9% to $164.7 million.
• The Surfactants segment, accounting for 72% of consolidated net sales, saw its operating income decrease by 40% in Q3 and 16% for the nine months, primarily due to lower average unit margins and startup expenses for the new Pasadena, Texas facility.
• The Polymers segment experienced a 4% decrease in net sales and an 8% decrease in operating income in Q3, but operating income increased by 6% for the nine months, driven by an 8% increase in sales volume partially offset by lower selling prices.
• Specialty Products showed strong growth, with net sales increasing by 68% in Q3 and 32% for the nine months, and operating income rising by 158% and 33% respectively, mainly due to order timing fluctuations in the pharmaceutical business.
• Net interest expense increased significantly by 76% for the nine months, primarily due to lower U.S. capitalized interest income as the Pasadena, Texas facility became operational.
• The effective tax rate increased to 34.4% in Q3 2025 from a negative 10.7% in Q3 2024, and to 23.8% for the nine months from 18.9% in the prior year, due to unfavorable adjustments and a decrease in R&D tax credits.
• Corporate expenses decreased due to the non-recurrence of charges related to a criminal social engineering fraud event in 2024.

Sentiment

Score: 3

Explanation: The significant decline in net income and EPS for both the quarter and nine-month periods, coupled with a substantial drop in operating income for the largest segment (Surfactants) and increased interest and tax expenses, indicates a challenging financial performance. While sales and EBITDA showed growth, and Specialty Products performed well, the core profitability metrics are concerning. The non-recurrence of fraud-related expenses helped corporate overhead, but underlying operational issues in the main segment and higher costs weighed heavily on the bottom line.

Positives

• Consolidated net sales increased by 8% in Q3 2025 and 7% for the nine months, driven by higher average selling prices and increased sales volume.
• EBITDA increased by 6% in Q3 2025 to $56.1 million and by 9% for the nine months to $164.7 million, indicating improved operational cash flow before non-cash items.
• The Specialty Products segment demonstrated strong performance, with net sales up 68% in Q3 and 32% for the nine months, and operating income surging by 158% and 33% respectively.
• Polymer sales volume increased by 8% for both the three and nine months, with North American operations benefiting from a competitor's market exit in commodity phthalic anhydride.
• Corporate expenses decreased significantly due to the non-recurrence of a $3.3 million charge in Q3 2024 and a $6.8 million expense for the nine months related to a criminal social engineering fraud event.
• The new specialty alkoxylation facility in Pasadena, Texas, started up in April 2025, indicating strategic capacity expansion, despite initial startup costs.

Negatives

• Net income for Q3 2025 plummeted by 54.1% to $10.8 million, and diluted EPS decreased by 54.4% to $0.47.
• Net income for the first nine months of 2025 decreased by 10.9% to $41.9 million, with diluted EPS down 10.7% to $1.83.
• The Surfactants segment, the largest contributor to sales, experienced a 40% decline in operating income in Q3 and a 16% decline for the nine months, primarily due to lower average unit margins and startup expenses at the new Pasadena facility.
• Gross profit decreased by 6.2% in Q3 2025, indicating pressure on margins.
• Net interest expense increased by $3.2 million in Q3 and $7.1 million (76%) for the nine months, largely due to lower capitalized interest income post-Pasadena facility startup.
• The effective tax rate significantly increased to 34.4% in Q3 2025 and 23.8% for the nine months, impacted by unfavorable provision-to-return adjustments and reduced R&D tax credits.
• An additional $1.754 million was accrued for remediation expenses at the Elwood, Illinois (Millsdale) facility in Q2 2025 due to a change in remediation scope.
• A $1.126 million civil penalty from the USEPA for FIFRA violations was paid in July 2025, although $0.5 million was recovered from third parties.

Risks

• Volatility of raw material, natural gas, and electricity costs, as well as potential disruptions in their supply, could impact profitability.
• Disruptions in transportation or significant changes in transportation costs could affect operations and profitability.
• International business risks, including changes in global trade policy, tariffs, currency exchange controls, fluctuations in currency exchange rates, legal restrictions, and taxes, pose ongoing challenges.
• Unfavorable resolution of litigation against the company, particularly environmental and tax-related proceedings, could result in material liabilities.
• The company's operations are subject to extensive local, state, and federal environmental regulations, and increasingly stringent regulations may require additional unforeseen environmental expenditures.
• Cost overruns, delays, and miscalculations in capacity needs with respect to expansion or other capital projects could impact financial performance.
• The company is exposed to volatility in short-term interest rates, although it uses interest rate swaps to mitigate some of this risk.
• The Brazil National Treasury filed a rescission action against the company's Brazilian subsidiary to rescind its use of PIS/COFINS tax credits, which could result in material liability depending on the ultimate resolution.

Future Outlook

Management estimates total capital expenditures for 2025 will be in the range of $118.0 million to $123.0 million. The company believes its liquidity is sufficient to fund anticipated capital expenditures, working capital, dividends, and other planned financial commitments for the foreseeable future. The impact of the 2025 U.S. Tax Act is not currently expected to have a material impact on the company's financial results, position, liquidity, or cash flows in 2025. The sale of manufacturing assets in the Philippines is planned to close during the fourth quarter of 2025.

Management Comments

• Management believes that the disclosures are adequate and make the information presented not misleading.
• Management believes that the Company has made adequate provisions for the costs it is likely to incur with respect to legal and environmental claims.
• Management believes that the Company has no material liability at certain environmental sites and that these matters, individually and in the aggregate, will not have a material effect on the Company's financial position.
• Management believes that the Company's liquidity is sufficient to provide for potential increases in working capital requirements during 2025.
• Management believes it was in compliance with the covenants under its material debt agreements as of September 30, 2025.

Industry Context

Stepan Company operates in the specialty chemicals industry, providing intermediate chemicals for diverse applications including consumer and industrial cleaning, thermal insulation, coatings, adhesives, sealants, elastomers, and food/pharmaceuticals. The Surfactants segment, its largest, is influenced by demand in consumer products, agriculture, and oilfield markets. The Polymers segment is affected by the construction industry (rigid foam insulation) and competitive activity, as seen with the market exit of a competitor boosting phthalic anhydride sales volume. The Specialty Products segment benefits from demand in food, flavoring, nutritional supplement, and pharmaceutical applications, which can be subject to order timing fluctuations. The company's global operations expose it to foreign currency fluctuations and varying regional market demands.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company is involved in various legal proceedings, primarily related to environmental assessment, protection, and remediation matters, including sites in Maywood, New Jersey; DImperio Property, New Jersey; and Wilmington, Massachusetts.
• An additional $1.754 million was accrued in Q2 2025 for remediation expenses at the Elwood, Illinois (Millsdale) facility due to a change in the scope of planned remediation activities.
• The company received a Notice and Finding of Violation from the USEPA on March 26, 2024, alleging air regulation violations at its Elwood, Illinois (Millsdale) facility.
• The Brazil National Treasury filed a rescission action on June 12, 2023, against the company's Brazilian subsidiary to rescind its use of PIS/COFINS tax credits for the period from March 23, 2012, to March 15, 2017.
• A civil penalty of $1.126 million was assessed by the USEPA on March 19, 2025, for alleged violations of FIFRA associated with certain biocide products, which the company paid on July 2, 2025, and has recovered $0.5 million from third parties.

Stakeholder Impact

• Shareholders: Impacted by the significant decline in net income and diluted EPS, potentially affecting share price and dividend sustainability if trends continue.
• Employees: The company's U.S. and U.K. defined benefit pension plans are frozen, and profit sharing contributions are made to qualified retirement plans.
• Customers: The company's ability to pass through higher raw material costs to customers impacts sales prices, while product mix changes reflect evolving customer demand.
• Creditors: The company issued $75.0 million in senior unsecured notes, increasing its debt, but management believes it remains in compliance with debt covenants.
• Regulatory Authorities: Ongoing environmental and regulatory compliance costs, penalties, and legal proceedings demonstrate the company's exposure to regulatory scrutiny and potential liabilities.

Next Steps

• The company plans to close the sale of its manufacturing assets in Bauan, Batangas, Philippines, during the fourth quarter of 2025.
• Management will continue to analyze the impact of the 2025 U.S. Tax Act on financial results, position, liquidity, and cash flows.
• The company continues to pursue complete recovery of the remaining $0.626 million from third parties related to the USEPA FIFRA penalty.
• The company will continue to invest in equipment and facilities to comply with existing and future environmental regulations.

Key Dates

Recommendation

While Stepan Company demonstrated sales growth and increased EBITDA, the significant decline in net income and diluted EPS for both the quarter and nine-month periods is a major concern. The underperformance of the core Surfactants segment, coupled with higher interest and tax expenses, indicates profitability challenges. The strong performance of Specialty Products and the non-recurrence of prior fraud-related expenses offer some positives, but these are not enough to offset the overall decline in bottom-line results. Given the mixed financial signals, including revenue growth but profitability contraction, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to improve margins in its Surfactants segment, manage rising costs, and resolve ongoing legal and environmental contingencies before considering further investment.

Keywords

Specialty Chemicals, Surfactants, Polymers, Specialty Products, SEC Filing, 10-Q, Earnings Report, Chemical Manufacturing, Financial Performance, Environmental Liabilities, Debt, Capital Expenditures, Pasadena Facility, PIS/COFINS, FIFRA